Executive summary
Canada regulates peptides under the Food and Drugs Act (FDA, R.S.C. 1985, c. F-27) and Food and Drug Regulations (C.R.C., c. 870). Peptides are classified as drugs, natural health products (NHPs), or food ingredients based on composition, intended use, and claims. Most bioactive "research peptides" sold online are unauthorised drugs without a legal market pathway.
Authorities and legal categories
Health Canada: Therapeutic Products Directorate (TPD) — review; Regulatory Operations and Enforcement Branch (ROEB) — compliance and enforcement.
CBSA (Canada Border Services Agency): screens imports at ports of entry.
Provincial pharmacy regulatory authorities (e.g., OCP, OPQ, ACP, BC College of Pharmacists): enforce compounding standards.
NAPRA: develops model standards for pharmacy compounding.
Key instruments:
Food and Drugs Act (R.S.C., 1985, c. F-27).
Food and Drug Regulations (C.R.C., c. 870) — Part C (drugs).
Natural Health Products Regulations (SOR/2003-196).
Controlled Drugs and Substances Act (S.C., 1996, c. 19).
| Activity | Federal role | Provincial role | Verification record |
|---|---|---|---|
| Product authorization | Health Canada reviews the specific drug product | No market-authorization role is established here | Drug Product Database and the product's DIN |
| Clinical study | Health Canada authorizes a CTA under Part C, Division 5 | Research Ethics Board approval is also required | Current Health Canada authorization and study record |
| Manufacturing | Health Canada applies Establishment Licence and GMP requirements | Practice requirements may also apply to regulated professionals | Food and Drug Regulations |
| Pharmacy compounding | Health Canada policy defines the manufacturing/compounding boundary | Provincial pharmacy regulators enforce compounding standards | POL-0051 and the relevant provincial record |
| Import, sale, and advertising | Health Canada applies federal product rules; CBSA screens at the border | Local professional or pharmacy rules may also apply | Federal product authorization, Establishment Licence, and transaction-specific records |
- Federal, Health Canada: market authorization, clinical studies, and import, sale, and advertising.
- Provincial and territorial pharmacy regulators: pharmacy practice and compounding standards.
- Both feed a product- and activity-specific assessment.
- CCES and WADA are a sport overlay, not medicine approval.
Approved medicines
Approved peptide drugs (with Drug Identification Numbers) include insulin and analogues, Expansion of the abbreviation used in the monographs: glucagon-like peptide-1 receptor agonist. The atlas does not define the pharmacology of this class; see the monograph for what is documented about a specific compound. Источник определения: Neutral gloss; the abbreviation is printed on the tirzepatide monograph but the atlas does not define the class pharmacology · Глоссарий (semaglutide/Ozempic/Wegovy, liraglutide/ Victoza/Saxenda, tirzepatide/Mounjaro), teriparatide (Forteo), leuprolide (Lupron), octreotide (Sandostatin), desmopressin, calcitonin, and bacitracin (topical).
Source: Health Canada Drug Product Database, https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html
Investigational use
Clinical trials require a Clinical Trial Application (CTA) under Part C, Division 5 of the Food and Drug Regulations, plus Research Ethics Board approval. No trial may proceed without Health Canada authorisation.
Compounding/manufacturing
POL-0051 — Health Canada's Policy on Manufacturing and Compounding Drug Products distinguishes manufacturing (Establishment Licence + GMP) from compounding (exempt from drug approval if prescription-based, patient-specific). Compounding of "essentially a copy" of an approved drug is not compliant.
NAPRA Model Standards for Pharmacy Compounding (sterile, non-hazardous, hazardous). Sterile compounding requires compliance with CSA standard Z314.8. Provincial authorities enforce these standards.
Most peptide raw materials from "research chemical" suppliers do not meet compendial-grade quality expectations for compounding.
Import, sale, advertising, and online supply
Import: Food and Drug Regulations s. A.01.040 requires that every imported drug be manufactured in a GMP-equivalent facility and the importer hold an Establishment Licence. CBSA screens for unapproved peptides.
Personal import: Canadian residents generally may not import prescription drugs for personal use by mail or courier, subject to limited exceptions in GUI-0116. Visitors may bring a personal-use quantity under separate conditions. Rules differ for prescription drugs, non-prescription products, controlled substances, carried goods, and mailed shipments; a generic “30–90 day” allowance must not be applied across those categories.
Sale: FDA s. 8 prohibits sale of unapproved new drugs.
Advertising: FDA s. 9(1) prohibits false/misleading labelling. FDA s. 3 prohibits advertising therapeutic products for Schedule A diseases (cancer, diabetes, etc.) to the public.
Research-use-only products
No statutory "research use only" exemption exists in Canada. FDA s. 30.05 grants the Minister exemption power, but it is not routinely used for individual peptide products. "Research use only" labelling is a common carrier defence, not a recognised category. Products implicitly marketed for human use through health claims may constitute unauthorized drug promotion or supply, depending on intended use, claims, product and transaction facts.
Sport/anti-doping overlay
The World Anti-Doping Agency; its Prohibited List classifies many peptides as prohibited substances in sport. Источник определения: WADA and sport regulation brief · Глоссарий Prohibited List is enforced by the Canadian Centre for Ethics in Sport (CCES).
Controlled substances
Do not infer from The World Anti-Doping Agency; its Prohibited List classifies many peptides as prohibited substances in sport. Источник определения: WADA and sport regulation brief · Глоссарий status: sport prohibition and Canadian controlled-substance scheduling are separate legal systems. Check the current statutory schedule and the exact substance identity.
The current consolidated CDSA schedules reviewed for this snapshot do not name GHRP-2, GHRP-6, or ipamorelin. SOR/2026-71 concerned named synthetic opioids, not those peptides; this page therefore makes no controlled-substance claim for them. Any class-based coverage must be established from the current statutory text and case-specific legal analysis rather than inferred from WADA status.
Enforcement examples and uncertainty
CBSA routinely seizes shipments of unapproved peptides (BPC-157, TB-500, GHRPs) destined for consumers.
Health Canada has taken action against clinics promoting peptide therapies.
Uncertainty: the classification boundary between drug and NHP for short peptide sequences remains untested at scale.
Practical interpretation limits
This is general regulatory research, not legal advice. Classification can turn on composition, claims, intended use, route, supplier role, and facts not captured by a product name.
Related atlas pages: global framework, United States, cross-border supply, and WADA and sport.
Primary sources
Food and Drugs Act (R.S.C., 1985, c. F-27). https://laws-lois.justice.gc.ca/eng/acts/F-27/
Food and Drug Regulations (C.R.C., c. 870). https://laws-lois.justice.gc.ca/eng/regulations/C.R.C.,_c._870/
Natural Health Products Regulations (SOR/2003-196). https://laws-lois.justice.gc.ca/eng/regulations/SOR-2003-196/
Drug Product Database. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html
Controlled Drugs and Substances Act. https://laws-lois.justice.gc.ca/eng/acts/C-38.8/
NAPRA Compounding Standards. https://www.napra.ca